INTRODUCTION
Toxic epidermal necrolysis (TEN) is a rare, but very severe cutaneous disorder characterized by necrosis of keratinocytes leading to a loosening of the epidermis'**.
As a consequence, lifethreatening dehydration and severe infections may occur. TEN can occur as a result of an adverse reaction to drugs (i.e. Lye11 syndrome) or may be the result of staphylococcal toxins (i.e. staphylococcal scalded skin syndrome, SSSS)'. We report a case of TEN following treatment with a new antiepileptic drug (AED). Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine) has recently been developed for oral treatment of epilepsy. Clinical trials have shown that lamotrigine is efficacious in controlling epilepsp.
Contraindications to treatment are scarce, but include allergy. Reported sideeffects include: maculopapular rash, angioedema and Stevens-Johnson's syndrome. Minor sideeffects include diplopia, headache, dizziness, ataxia, GI-disturbances and restlessness, but may at least in part be attributed to increased side-effects of concommitant AEDs'.
sponse to flickerstimulation and not characteristic for juvenile myoclonic epilepsy. She had previously been treated with valproic acid, phenytoin and vigabatrin. Then she was witout antiepileptic medication for two months. Carbamazepine medication was started at 100 mg BID wih the intention to increase after two weeks, but as the patient had no reduction in seizures and as lamotrigine was a new possibility, carbamazepine was withdrawn and the patient was initated on lamotrigine 50mg/day. The dose was increased by 50 mg every four days. After 12 days she was on lamotrigine monotherapy 100 mg BID and was seizure-free. Seventeen days later (i.e. 29 days after initiation of lamotrigine monotherapy), the patient developed cutaneous symptoms and the medication was immediately changed to .phenobarbital 150 mg/day. Later medication was changed to a combination of phenobarbital 150 mg/day and clobazame 25 mg/day with acceptable effect on her seizures, but with sedative side-effects.
Clinical dermatology CASE REPORT

Clinical neurology
The patient was female and aged 24. She suffered from myoclonic seizures without loss of conciousness since the age of 21 years. The EEG was slightly abnormal without photosensitive re-
The patient presented no history of skin diseases and there were no skin diseases in the family. After 30 days on lamotrigine, she developed a macular rash on the trunk and extremities and she was initially examined at the emergency room before referral to the department of dermatology. Cutaneous symptoms hereafter rapidly progressed to confluence and she had involvement of conjunctivae (developing into symblepharon). She had lesions of the oral mucosa and had rash and systemic manifestations and two with symptoms described as Stevens-Johnson's syndrome. The remaining 25 patients were treated as out-patients. One of them had a StevensJohnson-like syndrome and another had erythema multiforme, six were treated with systemic steroids while the remaining 17 patients were described as having severe maculopapular rashes. In a more recent review of 3015 lamotrigine treated patients', serious rashes resulting in hospitalization occurred in eight patients. The rate of severe rashes thus seems to be about 1% and of Stevens-Johnson's syndrome about 0.1%. Our case seems to be the only case developing into TEN. The overall incidence of rashes leading to discontinuation is 2-3%, which is similar to the discontinuation rate with respect to carbamazepine treatment. It seems to be higher when the starting dose is high or if lamotrigne is given together with valproic acid'.". However, the rate of discontinuation is lower with a lower starting dose or when lamotrigine is given together with enzyme-inducing AEDs such as carbamazepine or phenytoin'.".
The present serious case with rash evolving to TEN occurred Fig. 1 
Diagnosis and treatment
of TEN is very important because of the high mortality rate". Deaths are mainly caused by hypovolemia and sepsis. Treatment with systemic steroids is a controversial issue. It is believed that the extension of necrolysis can be stopped by steroids. On the contrary, it is believed that steroids may lead to increased susceptibility to infections and impaired wound healing16. In the present case high doses of steroids were used, because the bullous affection was treated at an early stage.
As TEN is a lifethreatening condition, attention should be brought to cutaneous adverse drug reaction, not only to AEDs but to all drugs with the potential to elicit skin reactions. Regarding lamotrigine the newly recommended slow dose escalation' must be taken very seriously to minimize such adverse cutaneous drug reactions.
